scholarly journals Effect of patient’s sex on risk of recurrent venous thromboembolism: A meta-analysis

2007 ◽  
Vol 45 (2) ◽  
pp. 436
Author(s):  
S. McRae ◽  
H. Tran ◽  
S. Schulman
Keyword(s):  
Venous Thromboembolism ◽  
Meta Analysis ◽  
Recurrent Venous Thromboembolism

Diagnostic accuracy of D-Dimer testing for recurrent venous thromboembolism: A systematic review with meta-analysis.

2021 ◽  
Author(s):  
Matteo Nicola Dario Di Minno ◽  
Ilenia Calcaterra ◽  
Antimo Papa ◽  
Roberta Lupoli ◽  
Alessandro Di Minno ◽  
...  
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Diagnostic Accuracy ◽  
Meta Analysis ◽  
Recurrent Venous Thromboembolism ◽  
D Dimer

scholarly journals Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis

Thrombosis ◽  
2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
Aaron B. Holley ◽  
Christopher S. King ◽  
Jeffrey L. Jackson ◽  
Lisa K. Moores
Keyword(s):  
Venous Thromboembolism ◽  
Major Bleeding ◽  
Data Extraction ◽  
Meta Analysis ◽  
Vitamin K Antagonists ◽  
Secondary Prophylaxis ◽  
First Episode ◽  
Short Course ◽  
Recurrent Venous Thromboembolism ◽  
Prospective Trials

Introduction. Controversy remains over the optimal length of anticoagulation following idiopathic venous thromboembolism. We sought to determine if a longer, finite course of anticoagulation offered additional benefit over a short course in the initial treatment of the first episode of idiopathic venous thromboembolism. Data Extraction. Rates of deep venous thrombosis, pulmonary embolism, combined venous thromboembolism, major bleeding, and mortality were extracted from prospective trials enrolling patients with first time, idiopathic venous thromboembolism. Data was pooled using random effects meta-regression. Results. Ten trials, with a total of 3225 patients, met inclusion criteria. For each additional month of initial anticoagulation, once therapy was stopped, recurrent venous thromboembolism (0.03 (95% CI: −0.28 to 0.35); ), mortality (−0.10 (95% CI: −0.24 to 0.04); ), and major bleeding (−0.01 (95% CI: −0.05 to 0.02); ) rates measured in percent per patient years, did not significantly change. Conclusions: Patients with an initial idiopathic venous thromboembolism should be treated with 3 to 6 months of secondary prophylaxis with vitamin K antagonists. At that time, a decision between continuing with indefinite therapy can be made, but there is no benefit to a longer (but finite) course of therapy.

scholarly journals Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis

BMJ Open ◽  
2014 ◽  
Vol 4 (7) ◽  
pp. e005674-e005674 ◽  
Author(s):  
L. C. Lopes ◽  
J. Eikelboom ◽  
F. A. Spencer ◽  
E. A. Akl ◽  
C. Kearon ◽  
...  
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Meta Analysis ◽  
Recurrent Venous Thromboembolism

Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 44 (04) ◽  
pp. 377-387
Author(s):  
Ana Terleira-Fernández ◽  
Ramón Lecumberri ◽  
Mª Suárez-Gea ◽  
Gonzalo Calvo-Rojas ◽  
Emilio Vargas-Castrillón ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Web Sites ◽  
Causes Of Death ◽  
Meta Analysis ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Recurrent Venous Thromboembolism ◽  
Anticoagulated Patients ◽  
Active Cancer

AbstractDeath is more frequent than nonfatal recurrent venous thromboembolism (VTE) and major bleeding after acute VTE. The analysis of the causes of death is fundamental to explore new strategies to reduce mortality rates in these patients. The authors performed a meta-analysis to analyze mortality and independently adjudicated causes of death in anticoagulated patients due to VTE, and to evaluate potential differences between different anticoagulant schemes. They searched MEDLINE and CENTRAL, from January 1, 2000, to January 31, 2017, and performed additional searches in Web sites of regulatory agencies, clinical trial registers, and conference proceedings. Two investigators independently selected studies and extracted the data. Study quality was assessed with the Cochrane Collaboration's tool for assessing the risk of bias in randomized studies. Seven prospective randomized trials in 29,844 patients (22,025 patient-year follow-up) were included, comparing dabigatran, rivaroxaban, apixaban, and edoxaban with the standard anticoagulant treatment of VTE. A total of 718 patients died during the follow-up (3.4% per year; 95% confidence interval [CI]: 2.3–4.8). The most frequent causes of death were cancer (42%), followed by VTE (20%), infections (13%), hemorrhage (6%), heart disease (4%), and stroke (2%). There were no differences in the overall survival and causes of death according to the anticoagulant type. Concomitant active cancer during the study was significantly associated with death (odds ratio: 15.2; 95% CI: 9.2–25.1). Cancer is the leading cause of death in contemporary VTE trials. Interventions beyond anticoagulation, particularly in patients with active cancer, are needed.

Sign in / Sign up

Export Citation Format

Share Document